Cancer pharmaceutical-B (stock code: 2171) voluntarily announced that it will present clinical data of its three CAR-T cell therapy products at the 66th American Society of Hematology (ASH) Annual Meeting in 2024. These products include Caikez® (CT053), CT071, and CT0590, targeting multiple myeloma (MM) and plasma cell leukemia (PCL) respectively. Caikez® was approved for marketing by the National Medical Products Administration on February 23, 2024, for the treatment of relapsed or refractory MM in adult patients who have progressed after at least 3 lines of treatment. CT071 and CT0590 are currently undergoing clinical trials in china. Sci-tech pharmaceutical is dedicated to innovative CAR-T cell therapy aimed at treating hematologic malignancies and solid tumors, and has established a research and development platform from target discovery to commercial-scale production. Summary and further information will be announced after November 5, 2024.

Cancer pharmaceutical-B (stock code: 2171) voluntarily announced that it will present clinical data of its three CAR-T cell therapy products at the 66th American Society of Hematology (ASH) Annual Meeting in 2024. These products include Caikez® (CT053), CT071, and CT0590, targeting multiple myeloma (MM) and plasma cell leukemia (PCL) respectively. Caikez® was approved for marketing by the National Medical Products Administration on February 23, 2024, for the treatment of relapsed or refractory MM in adult patients who have progressed after at least 3 lines of treatment. CT071 and CT0590 are currently undergoing clinical trials in china. Sci-tech pharmaceutical is dedicated to innovative CAR-T cell therapy aimed at treating hematologic malignancies and solid tumors, and has established a research and development platform from target discovery to commercial-scale production. Summary and further information will be announced after November 5, 2024.